Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease

BACKGROUND: Respiratory syncytial virus (RSV) is a viral pathogen that causes annual epidemics of lower respiratory tract infection with substantial morbidity and mortality in young children, especially those with congenital heart disease (CHD). Palivizumab is the only immunoprophylaxis therapy appr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Saudi Med
Autori principali: Mohammed, Mohammed Hassan A., Agouba, Rihab, Obaidy, Islam El, Alhabshan, Fahad, Abu-Sulaiman, Riyadh
Natura: Artigo
Lingua:Inglês
Pubblicazione: King Faisal Specialist Hospital and Research Centre 2021
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7868616/
https://ncbi.nlm.nih.gov/pubmed/33550912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5144/0256-4947.2021.31
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi